Extension of the intensive phase reduces unfavourable outcomes with the 8-month thioacetazone regimen.

Armand Van Deun; K. J. M. Aung; M Salim; Mahmoud Ali; Moumita Naha; P. K. Das; Md. Anwar Hossain; De Clercq Erik

Related publications

Article2012

Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout

K. J. M. Aung, De Clercq Erik, Md Ashraf Ali, Sowjanya Naha, S. Roy, Md. A. Taleb, Md. A. Hossain, Leen Rigouts, Aysel Gumusboga, Armand Van Deun

Article2015

Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study

Shaji Kumar, Jae Hoon Lee, Meletios A Dimopoulos, Evangelos Terpos, Efstathios Kastritis, Wee Joo Chng, Artur Jurczyszyn, Hiroshi Handa, Shuji Ozaki, Xavier Leleu, Philippe Moreau, Juan José Lahuerta, Chaim Shustik, Daniel D. Waller, Meral Beksaç, Ravi Vij, Kihyun Kım, Jin Seok Kim, Ashraf Badros, Melissa Alsina, Brian G.M. Durie

Article2016

Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important

Meletios A Dimopoulos, Μαρία Ρούσσου, Nikolaos Kanellias, Maria Gavriatopoulou, Magdalini Migkou, Ioannis Panagiotidis, Evangelos Eleutherakis‐Papaiakovou, Dimitriοs Ziogas, Despina Fotiou, Stavroula Giannouli, Panagiotis Tsirigotis, Christos Poziopoulos, Sossana Delimpasi, Despoina Mparmparoussi, Charis Matsouka, Kostas Konstantopoulos, Evangelos Terpos, Efstathios Kastritis

Article2023

P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE-TREATED WITH A LENALIDOMIDE-BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Ioanna Dialoupi, Evgenia Verrou, Kyriaki Manousou, Stavros Gkolfinopoulos, Magdalini Migkou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios A Dimopoulos

Article2025

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Vladimir Vorobyev, Hang Quach, Ivan Špıčka, Jakub Radocha, Paweł Robak, Kihyun Kım, Michèle Cavo, Kazuhito Suzuki, S. Yousuf Zafar, Ainslee Moore, Michael Duggan, Kristin Morris, Amy Phillips-Jones, Margaret Polinkovsky, Jayleen Grams, Ianire Garrobo-Calleja, Elisabet E. Manasanch, Brandon E. Kremer,